Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Center for Health Promotion, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Gastroenterology. 2016 Sep;151(3):481-488.e1. doi: 10.1053/j.gastro.2016.06.001. Epub 2016 Jun 7.
BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD) has been associated with subclinical atherosclerosis in cross-sectional studies. We investigated the longitudinal association of NAFLD with the development of subclinical carotid atherosclerosis.
We performed a retrospective cohort study of 8020 adult men (average age, 49.2 y) without carotid atherosclerosis at baseline who underwent repeated health check-up examinations from January 1, 2005, through December 31, 2013. NAFLD status was diagnosed by ultrasonography and classified into 4 groups based on baseline and follow-up findings: none, developed, regressed, or persistent NAFLD. Subclinical carotid atherosclerosis was measured by ultrasound.
The age-adjusted hazard ratio for subclinical carotid atherosclerosis development comparing participants with persistent NAFLD with those without NAFLD was 1.23 (95% confidence interval [CI], 1.13-1.35; P < .001). The association persisted after adjustment for smoking, alcohol, body mass index, and weight change (hazard ratio, 1.13; 95% CI, 1.03-1.25; P = .014), but disappeared after adjustment for metabolic variables. The hazard ratio, comparing subjects with regression of NAFLD vs those with persistent NAFLD, was 0.82 (95% CI, 0.69-0.96; P = .013). The risk of subclinical carotid atherosclerosis development also was higher among participants with a high NAFLD fibrosis score, fibrosis-4 scores, or levels of γ-glutamyl transferase at baseline.
In a large cohort study, persistent NAFLD was associated with an increased risk of subclinical carotid atherosclerosis development. This association was explained by metabolic factors that could be potential mediators of the effect of NAFLD. Markers of liver fibrosis also were associated with subclinical carotid atherosclerosis development. Prospective studies are needed to determine whether treatment of NAFLD can reduce this risk.
非酒精性脂肪性肝病(NAFLD)与横断面研究中的亚临床动脉粥样硬化有关。我们研究了 NAFLD 与亚临床颈动脉粥样硬化发展之间的纵向关联。
我们对 8020 名无基线颈动脉粥样硬化的成年男性(平均年龄 49.2 岁)进行了回顾性队列研究,这些男性在 2005 年 1 月 1 日至 2013 年 12 月 31 日期间接受了重复健康检查。通过超声检查诊断 NAFLD 状态,并根据基线和随访结果将其分为 4 组:无、新发、消退或持续 NAFLD。通过超声测量亚临床颈动脉粥样硬化。
与无 NAFLD 的参与者相比,持续存在 NAFLD 的参与者发生亚临床颈动脉粥样硬化的年龄调整风险比为 1.23(95%置信区间 [CI],1.13-1.35;P<.001)。在调整了吸烟、饮酒、体重指数和体重变化后,这种关联仍然存在(风险比,1.13;95%CI,1.03-1.25;P=.014),但在调整了代谢变量后,这种关联消失了。与持续存在 NAFLD 的患者相比,NAFLD 消退的患者的风险比为 0.82(95%CI,0.69-0.96;P=.013)。基线时 NAFLD 纤维化评分、纤维化-4 评分或γ-谷氨酰转移酶水平较高的患者发生亚临床颈动脉粥样硬化的风险也较高。
在一项大型队列研究中,持续存在的 NAFLD 与亚临床颈动脉粥样硬化发展的风险增加有关。这种关联可以用代谢因素来解释,代谢因素可能是 NAFLD 效应的潜在介质。肝纤维化标志物也与亚临床颈动脉粥样硬化的发展有关。需要前瞻性研究来确定是否治疗 NAFLD 可以降低这种风险。